We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genetix Completes Acquisition of Applied Imaging Corp
News

Genetix Completes Acquisition of Applied Imaging Corp

Genetix Completes Acquisition of Applied Imaging Corp
News

Genetix Completes Acquisition of Applied Imaging Corp

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genetix Completes Acquisition of Applied Imaging Corp"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genetix Ltd (New Milton, UK), has completed the acquisition of Applied Imaging Corp (San Jose, USA). Through the integration of Genetix breakthrough cell biology platforms (ClonePix FL and CloneSelect Imager) and Applied Imaging’s Ariol and CytoVision product lines, the company can now deliver systems that track the progress of drug discovery from the research laboratory through to the clinic.

ClonePix FL and CloneSelect Imager, along with their dedicated reagents and consumables, have revolutionised the generation, selection and management of mammalian cell lines for biopharmaceutical and drug discovery. Eliminating laborious manual procedures and screening very large numbers of cells, Genetix systems shorten timescales from weeks to days. Cell culture is simplified, turning large scale, high throughput screening from a facility-based activity into a benchtop process.

The Ariol pathology instrumentation and the CytoVision software, enable the nature of tumours to be studied at protein biomarker level. This is invaluable in the drug discovery process - for target discovery and as a monitor of therapeutic response and predictor of treatment effectiveness.

Advertisement